Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence

Abstract

Botulinum toxin type A (BoNT-A) therapy has gained wide acceptance in the management of spasticity in cerebral palsy (CP). Clinical experience from numerous case reports and series, retrospective and prospective open label cohort studies, and randomized controlled trials (RCT) has grown over the past 10 years. Several independent systematic reviews on the role of BoNT-A for upper and lower limb spasticity have been written by various authors. The objective of this paper is to summarize past systematic reviews and recent RCT not yet included in the systematic reviews that assess the effectiveness of BoNT-A in upper and lower limb spasticity in children with CP. We reviewed four Class II RCT discussed in five independent systematic reviews and two new Class II trials on the use of BoNT-A alone or with occupational therapy compared to placebo or occupational therapy alone in children with upper limb spasticity. There were 229 children recruited in these six trials and of those, 115 children received BoNT-A in the upper limbs. Five of six RCT showed a time limited decrease in muscle tone most especially at the wrist. Four of six trials showed improvement of hand function on a few specific functional tests. Four systematic reviews concluded that there is insufficient and inconsistent evidence to support or refute the effectiveness of BoNT-A in upper limb spasticity but one recent review recommended that BoNT-A should be considered as a treatment option in upper limb spasticity. For lower limb spasticity, we reviewed 13 RCT discussed in six systematic reviews and two new trials comparing BoNT-A with placebo or other rehabilitation modalities such as physiotherapy, occupational therapy, casting or electrical stimulation. In these studies, 617 children were recruited and of those, 360 children received BoNT-A in the lower limbs. There were six Class I and nine Class II trials. Three Class I trials documented significant improvement in gait pattern in children with gastrocnemius spasticity and one Class I study showed significant reduction in tone in the hip adductors. The most recent review establishes BoNT-A as an effective treatment for equinovarus deformity. Adverse events in these trials were mild and self-limited. The most common complaints were pain in the injection sites and transient weakness. BoNT-A is considered safe for use in children. In conclusion, there is now growing convincing evidence for the time limited beneficial effect of BoNT-A in decreasing muscle tone in children with upper and lower limbs spasticity associated with CP. Decrease muscle tone in the lower limbs translates to improved gait in CP children with spastic equinovarus however more systematic studies are necessary to show sufficient evidence for improved hand function from BoNT-A injection in the upper limbs.

This is a preview of subscription content, access via your institution.

References

  1. Ackman JD, Russman BS, Thomas SS et al (2005) Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol 47:620–627

    PubMed  Article  Google Scholar 

  2. Ade-Hall RA, Moore AP (2000) Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. The Cochrane Database of Systematic Reviews. The Cochrane Library

  3. Ashworth B (1964) Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192:540–542

    PubMed  CAS  Google Scholar 

  4. Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr L et al (2002) Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose ranging study. Dev Med Child Neurol 44:666–675

    PubMed  Article  CAS  Google Scholar 

  5. Bjornson K, Hays R, Graubert C et al (2007) Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 120:49–58

    PubMed  Article  Google Scholar 

  6. Bohannon RW, Smith MB (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206–207

    PubMed  CAS  Google Scholar 

  7. Bottos M, Benedetti MG, Salucci P (2003) Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol 45:758–762

    PubMed  CAS  Google Scholar 

  8. Boyd RN, Hays RM (2001) Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 8(Suppl 5):1–20

    PubMed  Article  Google Scholar 

  9. Boyd RN, Pliatsios V, Starr R, Wolfe R, Graham HK (2000) Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 42:32–41

    PubMed  Article  CAS  Google Scholar 

  10. Boyd RN, Dobson F, Parrott J, Love S, Oates J, Larson A et al (2001) The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol 8(Suppl 5):109–119

    PubMed  Article  Google Scholar 

  11. Cardoso ES, Rodriguez MD, Barroso M et al (2006) Botulinum toxin type A for the treatment of spastic equines foot in cerebral palsy. Pediatr Neurol 34:106–109

    PubMed  Article  Google Scholar 

  12. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK (1997) Botulinum toxin A in the hemiplegic upper limb: a double blind trial. Dev Med Child Neurol 39:185–193

    PubMed  CAS  Google Scholar 

  13. Corry IS, Cosgrove AP, Duffy CM (1998) Botulinum toxin A compared with stretching casts in the treatment of spastic equines: a randomized prospective trial. J Pedia Orthop 18:304–311

    Article  CAS  Google Scholar 

  14. DeMatteo C, Law M, Russell D, Pollock N, Rosenbaum P, Walter S (1992) QUEST: quality of upper extremity skills test. McMaster University, Neurodevelopmental Clinical Research Unit, Hamilton

  15. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, Eyssen M, Pauwels P, De Cock P (2001) A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 8(Suppl 5):75–87

    PubMed  Article  Google Scholar 

  16. Detrembleur C, Lejeune TM, Renders A (2002) Botulinum toxin and short term electrical stimulation in the treatment of equinus in cerebral palsy. Mov Disord 17:162–169

    PubMed  Article  CAS  Google Scholar 

  17. Edlund W, Gronceth G, SoY, Franklin G (2004) American Academy of Neurology Clinical Practice Guideline Process Manual

  18. Fehlings D, Rang M, Glazier J, Steele C (2000) An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 137:331–337

    PubMed  Article  CAS  Google Scholar 

  19. Fisher AG (2003) AMPS: assessment of motor and process skills volume 1: development, standardization, and administration manual, 5th edn. Three Star Press Inc, Fort Collins

    Google Scholar 

  20. Flett PJ, Stern LM, Waddy H (1999) Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediat Child Health 35:71–77

    Article  CAS  Google Scholar 

  21. Garces K, McCormick A, McGahan L, Skidmore B (2005) Botulinum toxin A for upper and lower limb spasticity: a systematic review. Can Coordin Off Health Technol Assess 51:1–70

    Google Scholar 

  22. Goldstein M (2004) The treatment of cerebral palsy: what we know, what we don’t know. J Pediatr 145:S42–S45

    PubMed  Article  Google Scholar 

  23. Hagglund G, Andersson S, Duppe H, Pedertsen HL, Nordmark E, Westbo L (2005) Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop 14:269–273

    Google Scholar 

  24. Haley SM, Coster SJ, Ludlow LH, Haltiwanger JT, Andrellos PJ (1992) Pediatric evaluation of disability inventory (PEDI): development, standardization, and administration manual. New England Medical Center and PEDI Research Group, Boston

    Google Scholar 

  25. Heinen F, Molenaers G, Fairhurst C, Carr LJ, Desloovere K, Valayer EC, Morel E, Papavassiliou AS, Tedroff K, Pascual-Pascual SI, Bernert G, Berweck S, Di Rosa G, Kolanowski E, Krageloh-Mann I (2006) European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 15:215–225

    Article  Google Scholar 

  26. Johnson LM, Randall MJ, Reddihough DS, Oke LE, Byrt TA, Bach TM (1994) Development of a clinical assessment of quality of movement for unilateral upper-limb function. Dev Med Child Neurol 36:965–973

    PubMed  CAS  Google Scholar 

  27. Kiresuk TJ, Smith A, Cardillo JE (1994) Goal attainment scaling: applications, theory, and measurement. Lawrence Erlbaum Associates, Hillsdale

    Google Scholar 

  28. Koman LA, Mooney JP, Smith BP et al (1993) Management of spasticity in cerebral palsy with botulinum toxin A: preliminary investigation. J Pediatr Orthop 13:489–495

    PubMed  CAS  Google Scholar 

  29. Koman LA, Mooney JF, Smith BP (1994) Management of spasticity in cerebral palsy with Botulinum A toxin: report of a preliminary, randomized, double blind trial. J Pediatr Orthop 14:299–303

    PubMed  CAS  Google Scholar 

  30. Koman LA, Mooney JF, Smith BP, Walker F, Leon JM, BOTOX Study Group (2000) Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 20:108–115

    PubMed  Article  CAS  Google Scholar 

  31. Lannin N, Scheinberg A, Clark K (2006) AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections. Dev Med Child Neurol 48:533–539

    PubMed  Article  Google Scholar 

  32. Law M, Baptiste S, Carswell A, McColl MA, Polatajko H, Pollock N (1998) Canadian occupational performance measure, 2nd edn. Canadian Association of Occupational Therapists, Toronto

    Google Scholar 

  33. Love SC, Valentine JP, Blair EM, Price CJ, Cole JH, Chauvel PJ (2001) The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial. Eur J Neurol 8(Suppl 5):50–58

    PubMed  Article  Google Scholar 

  34. Lowe K, Novak I, Cusick A (2006) Low dose/high concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 48:170–175

    PubMed  Article  Google Scholar 

  35. Lukban MB, Fojas MS, Avendano EL, delos Reyes FA, Ignacio SD, Rosales RL (2006) The management of spasticity in children with cerebral palsy: Consensus Statement of the Philippine Society of Neurorehabilitation. Neurorehabil Neural Repair 20:198–199 (abstract)

    Google Scholar 

  36. Maathuis KG, van der Schans CP, van Iperen A, Rietman HS, Geertzen JH (2005) Gait in children with cerebral palsy: observer reliability of Physician Rating Scale and Edinburgh Visual Gait Analysis Interval Testing scale. J Pediatr Orthop 25:268–272

    PubMed  Article  Google Scholar 

  37. Mall V, Heinen F, Siebel A et al (2006) Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 48:10–13

    PubMed  Article  Google Scholar 

  38. Mathrowitz V, Weber K, Kashman N, Volland G (1985) Adult norms for the nine hole peg test of finger dexterity. Occup Ther J Res 5:24–38

    Google Scholar 

  39. Panicker JN, Muthane UB (2003) Botulinum toxins: pharmacology and its current therapeutic evidence for use. Neurology India 51:455–460

    PubMed  CAS  Google Scholar 

  40. Park ES, Rha D (2006) Botulinum toxin type A injection for management of upper limb spasticity in children with cerebral palsy: a literature review. Yonsei Med J 47:589–603

    PubMed  CAS  Article  Google Scholar 

  41. Pidcock FS (2004) The emerging role of the therapeutic botulinum toxin in the treatment of cerebral palsy. J Pediatr 145:S33–S35

    PubMed  Article  CAS  Google Scholar 

  42. Randall MJ, Johnson LM, Reddihough DS (1999) The Melbourne assessment of unilateral upper limb function. Royal Children’s Hospital Melbourne, Melbourne

    Google Scholar 

  43. Reeuwijk A, van Schei PEM, Becher JG, Kwakkei G (2006) Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic review. Clin Rehabil 20:375–387

    PubMed  Article  Google Scholar 

  44. Rosales RL (2008) Chua-Yap A: evidence-based systematic review on the efficacy and safety of botulinum toxin therapy in post-stroke spasticity. J Neural Transm 115:617–623

    PubMed  Article  CAS  Google Scholar 

  45. Rosales RL, Dressler D, Bigalke H (2006) Pharmacologic differences between botulinum toxins. Eur J Neurol 13:2–10

    PubMed  Article  Google Scholar 

  46. Rosenbaum P, Stewart D (2004) The World Health Organization International Classification of Functioning, Disability, and Health: a model to guide clinical thinking, practice and research in the field of cerebral palsy. Semin Pediatric Neurol 11:5–10

    Article  Google Scholar 

  47. Ruiz FJ, Guest JF, Lehmann A, Davie AM, Guttler K, Schluter O, Dreiss G (2004) Costs and consequences of botulinum toxin type A use management of children with cerebral palsy in Germany. Eur J Health Econ 5:227–235

    PubMed  Article  Google Scholar 

  48. Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S (1989) The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 31:341–352

    PubMed  CAS  Article  Google Scholar 

  49. Russman BS, Tilton A, Gormley ME (1997) Cerebral palsy: a rational approach to a treatment protocol and the role of botulinum toxin in treatment. Muscle Nerve 20(Suppl 6):S1–S11

    Google Scholar 

  50. Russo RN, Crotty M, Miller MD et al (2007) Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial. Pediatrics 119:1149–1158

    Article  Google Scholar 

  51. Sanger TD, Kukke SN, Sherman-Levine S (2007) Botulinum toxin improves the speed of reaching in children with cerebral palsy and arm dystonia: an open-label, dose escalation pilot study. J Child Neurology 22:116–122

    Article  Google Scholar 

  52. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, Becher JG (2007) Effect of multilevel botulinum toxin A and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol 36:30–39

    PubMed  Article  Google Scholar 

  53. Schwerin A, Berweck S, Fletzek IM, Helnen F (2004) Botulinum toxin B treatment in children with spastic movement disorders: a pilot study. Pediatr Neurol 31:109–113

    PubMed  Article  Google Scholar 

  54. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y (2008) Assessment: botulinum neurotoxin for the treatment of spasticity (an evidenced based review). Neurology 70:1691–1698

    PubMed  Article  CAS  Google Scholar 

  55. Speth LA, Leffers P, Janssen-Potten YJ (2005) Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 47:468–473

    PubMed  Article  CAS  Google Scholar 

  56. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ (1999) Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 10:1–9

    PubMed  Article  CAS  Google Scholar 

  57. Tardieu G, Shentoub S, Delarue R (1954) A la recherche d’une technique de mesure de la spasticite imprime avec le periodique. Neurologique 91:143–144

    CAS  Google Scholar 

  58. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH (2000) Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 83:481–487

    PubMed  Article  CAS  Google Scholar 

  59. Varni JW, Seid M, Kurtin PS (2001) PedsQL4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care 39:800–812

    PubMed  Article  CAS  Google Scholar 

  60. Wallen M, O’Flaherty SJ, Waugh MC (2007) Functional outcomes of intramuscular botulinum toxin type A and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil 88:1–10

    PubMed  Article  Google Scholar 

  61. Wasiak J, Hoare B, Wallen M (2004) Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev (4):1–25 (CD003469)

  62. Waters E, Salmon L, Wake M, Wright M, Hesketh K (1999) Australian authorised adaptation of the child health questionnaire. Centre for Community Child Health, Royal Children’s Hospital Melbourne, Melbourne

Download references

Acknowledgments

We thank the members of the technical panel of the Philippine Society of Neurorehabilitation who appraised the early studies on BoNT-A: Dr. Myrna S. Fojas, Dr. Ermenilda L. Avendano, Dr. Fe A. de los Reyes and Dr. Sharon D. Ignacio.

Conflict of interest statement

None.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Marissa Barlaan Lukban.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lukban, M.B., Rosales, R.L. & Dressler, D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J Neural Transm 116, 319–331 (2009). https://doi.org/10.1007/s00702-008-0175-8

Download citation

Keywords

  • Botulinum toxin
  • Spasticity
  • Cerebral palsy
  • Review